CClinicalTrials.gg
CompletedNCT06724068Updated Dec 12, 2024

Diabetes, Insulin Resistance and Body Composition

An observational study in Insulin Resistance, Diabetes, sponsored by Xuan Song. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by Xuan Song · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
515
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this retrospective study is to learn about the correlation between diabetes, insulin resistance and body compositions.

The main question[s] it aims to answer are:

  • [The difference of body composition between the individuals of insulin resistance and diabetes]
  • [The effect of diabetes on body composition]
02

Conditions studied

  • Insulin Resistance, Diabetes
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 515 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

This is the only study on the registry with Xuan Song as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study includes adult patients aged 18 years and older who were diagnosed with type 2 diabetes mellitus. The population consists of individuals with documented medical records, including diabetes duration, glycemic control data (HbA1c levels), and body composition measurements such as muscle mass assessments. The study also includes a control group of non-diabetic individuals matched by age and sex to enable comparative analysis.

Inclusion criteria

  1. Adults aged 18 years and older.
  2. Diagnosed with type 2 diabetes mellitus according to recognized diagnostic criteria.
  3. Availability of complete body composition data (e.g., DXA measurements).
  4. Documented HbA1c levels and other glycemic control data.
  5. Continuous medical records available during the study period

Exclusion criteria

Exclusion Criteria:

  1. Presence of other severe metabolic diseases, such as liver failure or kidney failure.
  2. Use of medications affecting muscle mass (e.g., glucocorticoids) for more than three months.
  3. History of malignancy or ongoing treatment for cancer.
  4. Missing critical research data (e.g., diabetes duration or HbA1c levels).
  5. History of surgeries causing significant body composition changes (e.g., bariatric surgery).
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
515 participants (actual)
Patient registry
No

Groups and cohorts

  • Diabetes

    Other: Diabetes,Insulin resistance,Control

  • Insulin resistance

    Other: Diabetes,Insulin resistance,Control

  • Control

    Other: Diabetes,Insulin resistance,Control

Interventions

  • OtherDiabetes,Insulin resistance,Control

    This retrospective study uses medical records and diagnostic data from patients with type 2 diabetes and healthy controls obtained from Qianfoshan Hospital from2019 to 2022

06

What researchers measure

Primary outcomes

  1. Prevalence of Sarcopenia in Diabetic Patients

    The proportion of diabetic patients diagnosed with sarcopenia, assessed based on measurements of muscle mass, muscle strength, and physical performance. Sarcopenia will be defined according to AWGS 2019 and EWGSOP2

    Time frame: Retrospective analysis of data collected between2019 and 2022

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University
    Jinan, Shandong 250000, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06724068
Lead sponsor
Xuan Song
Responsible party
Xuan Song (Principal Investigator, Qianfoshan Hospital) — Sponsor-investigator
First posted
Dec 9, 2024
Start date
Dec 17, 2021
Primary completion
Aug 31, 2022
Completion
Aug 31, 2022
Last update
Dec 12, 2024

Study contacts

Song Xuan, Doctor
principal investigator · The First Affiliated Hospital of Shandong First Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion